ACADIA Pharmaceuticals Inc. $ACAD Shares Acquired by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 31.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,026,044 shares of the biopharmaceutical company’s stock after purchasing an additional 478,941 shares during the period. Pictet Asset Management Holding SA’s holdings in ACADIA Pharmaceuticals were worth $44,736,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $26,000. Transamerica Financial Advisors LLC raised its stake in shares of ACADIA Pharmaceuticals by 304.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,005 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,185 shares during the period. Finally, Leonteq Securities AG acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $52,000. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on ACAD shares. Bank of America boosted their target price on shares of ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday. Canaccord Genuity Group raised their price objective on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings cut shares of ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. JPMorgan Chase & Co. boosted their price objective on shares of ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Finally, HC Wainwright lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Tuesday. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.59.

ACADIA Pharmaceuticals News Summary

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Bank of America raised its price target on ACADIA Pharmaceuticals from $29 to $30 and reiterated a buy rating, signaling confidence that the stock still has meaningful upside from current levels. Benzinga article
• Positive Sentiment: European regulators advanced Daybue toward approval for Rett syndrome after a positive CHMP opinion, a key catalyst that could expand ACADIA’s international sales opportunity if the European Commission gives final approval. Yahoo Finance article
• Positive Sentiment: Canaccord Genuity also increased its price target on ACADIA and kept a buy rating, reinforcing the view that recent commercial progress and Europe-related news could support further gains. Benzinga article
• Neutral Sentiment: Commentary from analysts and market watchers notes that ACADIA has seen strong recent volume and momentum, but some warn that earnings estimate trends may limit near-term follow-through unless fundamentals continue improving. Yahoo Finance article
• Neutral Sentiment: Additional coverage highlighted ACADIA’s steady commercial progress with Nuplazid and Daybue, while noting that pipeline assets like remlifanserin remain higher-risk catalysts rather than near-term certainty. Seeking Alpha article

Insider Buying and Selling

In related news, insider James Kihara sold 5,401 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total value of $114,393.18. Following the sale, the insider owned 24,509 shares of the company’s stock, valued at approximately $519,100.62. This represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the sale, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This trade represents a 5.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 13,978 shares of company stock valued at $302,819. Corporate insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Trading Up 0.4%

Shares of NASDAQ ACAD opened at $25.30 on Wednesday. The stock has a market cap of $4.33 billion, a price-to-earnings ratio of 11.50, a PEG ratio of 31.64 and a beta of 0.83. ACADIA Pharmaceuticals Inc. has a 52 week low of $19.69 and a 52 week high of $28.35. The company’s 50-day moving average price is $21.96 and its 200 day moving average price is $23.42.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). ACADIA Pharmaceuticals had a return on equity of 9.61% and a net margin of 34.30%.The business had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. During the same quarter in the previous year, the firm posted $0.11 EPS. The business’s revenue was up 9.7% on a year-over-year basis. As a group, research analysts expect that ACADIA Pharmaceuticals Inc. will post 0.37 earnings per share for the current year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.